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visual categories could form the basis for a better under-
standing of the nature of the differences between the
processing of these categories.
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Recent reports have overturned a series of dogmas
that have been well entrenched in the neuroscience lit-
erature concerning NMDA-type glutamate receptors
(NMDARs). The new data show that NMDARs exist on
the myelin sheath formed by oligodendrocytes, that
an uncompetitive NMDAR antagonist has successfully
passed human clinical trials, and that NMDARs trigger
multiple deleterious cascades to inflict cellular dam-
age on both neurons and glia during cerebral ischemia
(stroke). These recent findings bode well for clinical
intervention with NMDAR antagonists in more neuro-
logical disorders than previously thought, including
multiple sclerosis, cerebral palsy (periventricular
leukomalacia), and spinal cord injury.
The latest scientific myth to be dispelled concerns oligo-
dendrocytes, the glial cells that produce the myelin
sheath of axons in the brain. Previously, it was widely
held that oligodendrocytes have only AMPA (a-amino-
3-hydroxy-5-methyl-4-isoxazole propionic acid) and
kainate-type glutamate receptors that contribute to theirdemise. This dogma was recently refuted by work in
three independent laboratories and may have far-reach-
ing implications for the treatment of a variety of neuro-
logical disorders. The laboratories involved are those
of David Attwell (University College, London), Robert
Fern (University of Leicester), and Peter Stys (University
of Ottawa). The three groups published new work in
a single issue of Nature showing that N-methyl-D-aspar-
tate-type glutamate receptors (NMDARs) are prominent
on oligodendrocytes or their processes that myelinate
axons and that excessive influx of Ca2+ via NMDAR-
associated ion channels leads to damage of these cells.
Previously, NMDAR-type glutamate receptors were
known to exist on neurons and were thought to contrib-
ute to neuronal damage during ischemia and various
neurodegenerative disorders. However, NMDARs were
not generally thought to effect oligodendrocyte/myelin
injury because these cells were said to lack such recep-
tors. While there were some hints from immunocyto-
chemical evidence that NMDARs might exist on glial
cells, these data were largely ignored. A few groups
had previously reported the presence of functional
NMDARs on rat oligodendrocyte precursor cells from
neurohypophysial explants, on human dissociated
Mu¨ller cells from the retina, and on mouse astrocytic
processes in neocortical slices (Wang et al., 1996;
Puro et al., 1996; Schipke et al., 2001), but again the
widely-held view was that these receptors were rare or
not important on glial cells. Very recently, Lalo et al.
(2006) performed whole-cell recordings with patch elec-
trodes on astrocytes identified in culture or in slices pre-
pared from transgenic mice that express enhanced
green fluorescent protein under the control of the human
glial fibrillary acidic protein promoter. This group found
that functional NMDARs contribute to ionic currents in
cortical astrocytes and that these receptors are involved
in physiological neuron-to-astrocyte signal transmis-
sion. Thus, increasing evidence points to the fact that
functional NMDARs exist on glial cells, including both
astrocytes and oligodendrocytes.
Concerning the potential pathophysiological rele-
vance of these new findings, impairment of oligodendro-
cytes and myelination—leading to what is termed ‘‘white
matter’’ disease—is a major factor in hypoxic-ischemic
disease (stroke), cerebral palsy (periventricular leukoma-
lacia), spinal cord injury, and multiple sclerosis. Hence,
the presence of functional NMDARs on these cells im-
plies that NMDAR antagonists, heretofore thought not
to exert a large effect on these glial cells, might be able
to protect them from these disease processes.
In the first new paper considered here on cells of oli-
godendrocytic lineage (Ka´rado´ttir et al., 2005), David
Attwell’s group performed patch-clamp recordings from
rat oligodendrocyte precursors and from immature and
mature oligodendrocytes in slice preparations of cere-
bellum and corpus callosum. During both simulated is-
chemic conditions and with the application of glutamate,
currents were at least partially inhibited by NMDAR an-
tagonists. With a critical eye, one might say that these
currents were not robust and exhibited rundown. None-
theless, these recordings are technically quite demand-
ing and a real tour-de-force. In this context, they are quite
impressive and strongly support the existence of func-
tional NMDARs on these cells.
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dendrocytes in the developing mouse optic nerve. They
found that oxygen and glucose deprivation (to simulate
ischemia) produced damage to oligodendrocyte pro-
cesses in a Ca2+-dependent manner. Although blockade
of AMPA or kainate receptors protected oligodendro-
cyte cell bodies, they did not protect their processes.
Only NMDAR antagonists prevented this type of injury.
While most of these methods are indirect, taken to-
gether with the electrophysiology recordings of the Att-
well group, the evidence for NMDARs is fairly strong,
and the implications for an effect of NMDARs on oligo-
dendrocyte survival are provocative to say the least.
Finally, the group led by Peter Stys (Micu et al., 2006)
studied adult rat optic nerve and found that the Ca2+
concentration of myelin encasing the nerve dramatically
increased during chemically induced ischemia. NMDAR
antagonists, but not AMPA or kainate receptor antago-
nists, prevented this rise in Ca2+ and the consequent
myelin damage. In addition to the pathophysiological
significance of these findings, this report also raises
the possibility of physiological glutamate signaling
from axon to myelin mediated by NMDARs. Looking crit-
ically, this evidence for functional NMDARs on adult my-
elin is somewhat indirect, since Ca2+ imaging is involved
rather than direct electrophysiological recording of cur-
rents. However, coupled with immunocytochemical
data from all three labs for the presence of NMDAR sub-
units on oligodendrocytes, it is very hard to dismiss
these data, which imply that NMDARs are pathophysio-
logically relevant to oligodendrocyte and myelin func-
tion. Nonetheless, to be balanced and given the com-
plexities of myelin, we must acknowledge that with
present techniques it is not possible to directly show
the presence of functional NMDARs on adult myelin,
e.g., with patch-clamp recording techniques.
Interestingly, all three of these studies suggested that
the NMDAR-mediated currents of oligodendrocytes
were made up of not only NR1 and various NR2 NMDA
receptor subunits but also NR3A subunits. As we and
our colleagues had previously shown (Das et al., 1998;
Sasaki et al., 2002), NR3 subunits can render NMDARs
much less sensitive to blockade by Mg2+, as was indeed
found to the be case for the NMDARs on oligodendro-
cytes. Similarly, Lalo et al. (2006) reported that the
NMDAR-mediated currents of cortical astrocytes were
also highly resistant to Mg2+ block, raising the possibility
that NR3 subunits may contribute to those functional re-
ceptors as well.
But additional dogmas and myths form a virtual
shroud over the story of NMDARs in clinical medicine.
Long before NMDARs were shown to be on oligodendro-
cytes, the neurological community had very high hopes
of relieving damage to neurons after publication of the
landmark 1984 publication of Roger Simon, Brian Mel-
drum, and colleagues (Simon et al., 1984) showing that
excessive NMDAR activity underlays ischemic damage.
However, the myth arose that all NMDAR antagonists
failed in clinical trials. This misinformation was then
followed by the myth that the failure of clinical trials oc-
curred because white matter did not have NMDARs;
hence, NMDAR antagonists were said not to be use-
ful in preventing ischemic damage because white mat-
ter (axons and their surrounding myelin sheaths)and astrocytes are injured in addition to gray matter
(neurons).
In actuality, most NMDAR antagonists failed in clinical
trials because they could not be tolerated by humans at
neuroprotective doses (Lipton, 2006). Many basic sci-
ence and clinical studies did not even use neuroprotec-
tive doses of NMDARs, because such doses proved to
be too toxic or at least exhibited severe side effects.
After all, the NMDAR is responsible for normal synaptic
transmission contributing to long-term potentiation
(LTP) and other important processes in many areas of
the brain. Therefore, high-affinity, effective NMDAR an-
tagonists block normal brain activity and lead to intoler-
able side effects, such as hallucinations, sleepiness, and
even coma.
In fact, what was needed was a more gentle type of
NMDAR antagonist, one that relatively spared normal
synaptic activity while blocking excessive (pathological,
probably extrasynaptic) activity (Hardingham et al.,
2002). One such example of a clinically tolerated NMDAR
antagonist that has passed multiple clinical trials is
memantine, which was recently approved by the FDA
for the treatment of moderate-to-severe Alzheimer’s dis-
ease and is also used clinically in Europe for vascular
(multi-infarct or multiple stroke) dementia. While mem-
antine may also interact with a7-nicotinic and 5HT3
channels, its major mode of action at clinically used con-
centrations is at the NMDAR (Lipton, 2006). Our group
showed that memantine is clinically tolerated because
of its mode of action on the NMDAR—it is an uncompet-
itive antagonist that acts as an open-channel blocker,
and, most importantly, with a relatively fast ‘‘off rate.’’
This fast off rate is a critical factor contributing to its
low-affinity mechanism of action and thus to its clinical
tolerability; memantine prevents excessive NMDAR ac-
tivity while not accumulating in NMDAR-operated chan-
nels. Hence, it does not block subsequent physiological
neurotransmission. This mode of drug action has been
termed ‘‘Pathologically-Activated Therapeutics’’ or
PAT drugs, that is, a gentle tap compared to most
high-affinity drugs that manifest severe side effects, as
previously produced by Big Pharma (Lipton, 2006).
Another misconception arose recently when meman-
tine was shown to have only a modest effect on rodent
models of cerebral ischemia; in contrast, blocking Ca2+
influx occurring via acid-sensing channels (ASICs) was
more effective (Xiong et al., 2004). However, that report
used a submaximal dose of memantine, so the full neu-
roprotective yet clinically tolerated action of the drug
was not achieved (Chen et al., 1998). In point of fact,
a more recent publication in Neuron has shown that
NMDARs may be very important in neuronal cell death
from ischemia because excessive NMDAR activity leads
to phosphorylation and thus activation of ASICs (Gao
et al., 2005). Thus, both types of channels are important,
and these new studies converge to the contrarian view
that NMDARs may be even more critical in cerebral is-
chemia and other neurodegenerative disorders than ap-
preciated in recent years, bringing us full-circle back to
the original view espoused in 1984 (Simon et al., 1984).
For some, this may conjure up an Orwellian image of
NMDARs controlling the fate of neurons and glia, espe-
cially because of the date of that initial publication. In
contrast, others will express a new sense of optimism
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antine in Alzheimer’s disease may in fact lead to similar
treatment of cerebral ischemia, multiple sclerosis,
cerebral palsy, spinal cord injury, glaucoma, and there-
fore both white matter and gray matter diseases with
NMDAR antagonists. Time will tell if this premise holds
true, but at a minimum we can say that clinical neurolo-
gists are excited by these prospects (although hopefully
not overly excited, so as to avoid excitotoxic damage in
their own thinking).
As a challenge for the future, the new work shows that
white matter (oligodendrocytes and myelin) contain
NMDARs with NR3A subunits. NR3 subunits can change
the properties of NMDARs—rendering the channels
much less sensitive to Mg2+ blockade and therefore po-
tentially active even at the resting membrane potential.
Currently, there are no selective agonists or antagonists
for NR3 subunits. It will be important for future basic
science studies and possible clinical interventions to
further elucidate the properties of receptors containing
NR3 subunits and to develop appropriate drugs to se-
lectively and specifically interact with these receptors.
And concerning dogmas, we must continue to challenge
and reinterpret our findings with an open mind, a pas-
sionate heart, and an inquiring intellect.
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